_群馬大学TLO様：調査報告書（最終）
|
|
|
- よいかず えんの
- 7 years ago
- Views:
Transcription
1
2
3
4
5 1
6
7
8
9 1. 5
10
11 B
12
13
14 A B A B20089 J 10 92
15
16
17
18
19 1. A 42 GM1 15
20 AB B
21
22
23
24 20 1.
25 21 1.
26 22 1.
27 23 1.
28 24 1.
29 25 1.
30 26 1.
31 27 1.
32 1. 28
33 1. 29
34 30 1.
35 31 1.
36
37 1. 33
38 1. 34
39 1. 35
40 1. 36
41 1. 37
42 B
43 1. 39
44 1. 40
45
46 1. 42
47 1. 43
48
49 1. C- C C+ B- B B+ A- A A+ 45
50 1. C- C C+ B- B B+ A- A A+ 46
51 1. C- C C+ B- B B+ A- A A+ 47
52 1. C- C C+ B- B B+ A- A A+ 48
53 1. C- C C+ B- B B+ A- A A+ 49
54 1. C- C C+ B- B B+ A- A A+ 50
55 1. C- C C+ B- B B+ A- A A+ 51
56 2. 52
57
58 2-1 54
59 2-1 55
60 56 2-1
61 57 2-1
62 58 IPC 28,
63 59 2-1
64 , ,000 60
65 2-1 61
66 2-1 62
67 ,
68 2-1 64
69
70 2-1 PFIZER 66
71 2-1 30~40 67
72 2-1 NOVARTIS
73 <20;20-50;>50; /3(30%;30-59%;60%) /315;15-49;50 69
74 2-1 3<20;20-50;>50; /3(30%;30-59%;60%) /315;15-49;50 70
75 2-1 6,000 NOVARTIS MG 71
76 2-1 72
77 2-1 73
78 2-1 74
79 2-1 75
80 2-1 76
81 77 2-1
82
83 2-1 79
84 2-1 80
85 2-1 81
86
87 2-1 83
88 2-1 84
89
90 86 2-1
91 87 2-1
92
93 2-1 89
94 2-1 F* *F 90
95 2-1 F 91
96 2-1 F 92
97 2-1 F 93
98 2-1 94
99 2-1 F
100 2-1 F* *F 96
101 2-1 F 97
102 2-1 PCR F 98
103 2-1 99
104 2-1 F
105
106
107 2-2 ESiPS 103
108
109 2-2 IPC 7,
110 ,
111
112
113
114 2-2 60% 110
115 CURAGEN AMGENPFIZERCHIRON 111
116
117
118 <20;20-50;>50; /3(30%;30-59%;60%) /315;15-49;50 114
119 2-2 1,
120
121
122
123
124
125
126
127
128
129
130 2-2 F* 10 *F 126
131 2-2 F 127
132 2-2 F 128
133
134
135 2-2 F
136
137
138 2-3 DDS DDS 134
139 135 *1: *2: *3: 2-3
140 2-3 IPC 29,
141
142 2-3 GE MEDICAL SYSTEMS PHILIPS ELECTRONICS 138
143
144 2-3 PET 140
145 2-3 X CT3 MRI PET 141
146 2-3 BOSTON SCIENTIFIC MEDTRONIC 142
147 2-3 DDSCORDISBECTON DICKINSON DDS 143
148 GE MEDICAL SYSTEMS 144
149 2-3 XCT MRIGE MEDICAL SYSTEMS PHILIPS ELECTRONICS XCT MRI 145
150 PETPHILIPS ELECTRONICSGENERAL ELECTRIC PET 146
151
152
153 2-3 XCT PET 149
154 2-3 PET4 3<20;20-50;>50; /3(30%;30-59%;60%) /315;15-49;50 150
155 2-3 3,000-4,000 XCTMRIGE MEDICAL SYSTEMSPHILIPS ELECTRINICS PET PET 2003 BOSTON SCIENTIFIC MEDTRONIC XCTMRI XCT 151
156
157
158
159
160 2-3 XCTMRI6 XCT
161
162
163 2-3 XCT21 159
164
165 161 XCT CT34 CT XCT 2-3
166 2-3 XMRI XCT XCT 19 XCT 162
167
168 2-3 XCTF* 20 XCT *F 164
169 2-3 X2 F 165
170 2-3 XCTF4C093CA23 FX F 166
171 2-3 X XX F 167
172 2-3 F 168
173 2-3 X F 169
174
175
176 2-3 XCT X X X F
177 2-3 F* 20 *F 173
178 2-3 F 174
179 2-3 S/N F 175
180 2-3 F 176
181 2-3 F 177
182
183
184 2-3 F F 180
185
186
187
188
189
190 186 IPC16, *1: *2: *3: 2-4
191 187 *1: *2: *3: 2-4
192
193
194 190 GENENTECH PFIZER 2-4
195
196
197
198 HOPKINSJOHNSUNIVERSITY MERCK AMGEN GLAXOSMITHKLINE MILLENNIUMPHARMACEUTICALS NOVARTIS F.HOFFMANN-LAROCHE WYETH 8 45 GLAXOSMITHKLINEBIOLOGICALS 7 47 THEREGENTSOFTHEUNIVERSITYOFCALIFORNIA 6 53 CHIRON PFIZER GENENTECH HOPKINSJOHNSUNIVERSITY MERCK AMGEN GLAXOSMITHKLINE MILLENNIUMPHARMACEUTICALS NOVARTIS F.HOFFMANN-LAROCHE WYETH 8 45 GLAXOSMITHKLINEBIOLOGICALS 7 47 THEREGENTSOFTHEUNIVERSITYOFCALIFORNIA 6 53 CHIRON PFIZER GENENTECH DIVERSA BASFAKTIENGESELLSCHAFT MONSANTOTECHNOLOGY 8 25 SYNGENTAPARTICIPATIONS 7 26 SYNGENTA DIVERSA BASFAKTIENGESELLSCHAFT MONSANTOTECHNOLOGY 8 25 SYNGENTAPARTICIPATIONS 7 26 SYNGENTA
199 BIOGENIDEC AMGEN WYETH SCHERING-PLOUGH CURAGEN DIVERSA PFIZER THEREGENTSOFTHEUNIVERSITYOFCALIFORNIA 7 26 CHIRON GENENTECH 2 68 EXELIXIS 1 13 BIOGENIDEC AMGEN WYETH SCHERING-PLOUGH CURAGEN DIVERSA PFIZER THEREGENTSOFTHEUNIVERSITYOFCALIFORNIA 7 26 CHIRON GENENTECH 2 68 EXELIXIS
200 % 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 196
201
202 2-4 3<20;20-50;>50; /3(30%;30-59%;60%) /315;15-49;50 198
203 GENENTECHPFIZER GENENTECHPFIZER
204
205
206
207
208
209
210
211
212
213
214
215
216 2-4 F* 10 *F 212
217 2-4 F cdna F 213
218 2-4 4C063QA01 DNAcDNAPCR 4B063QA18PCR F 214
219
220
221 2-4 F
222 2-4 F* 20 *F 218
223 2-4 4D006PA01 4D038AA08 F 219
224 2-4 4D028AA08 3 F 220
225
226
227 2-4 F
228 3. 224
229
230 3. 226
231
232 ,9294, ,
233 229 CSF Colony Stimulating Factor 3.
234 230 QOL 3.
235 3. PFIZERNOVARTIS
236 3. DNADNA Biogen idecgenentech 232
237 233 3.
238 3. PFIZER 5 234
239 3. PFIZER PFIZER PFIZER S VREMRSA PFIZER FDA2007/8HIV HIV 235
240 ,
241 3. PFIZER ASTRAZENECAMERCK 4 237
242 3. 3,
243 3. SHPS-1 239
244 Contact Information 240
第１章 製薬産業を取り巻く環境変化
2015 2007 5 1 2 2015 2007 5 103-0023 3-4-1 5F TEL : 03-5200-2681 FAX : 03-5200-2684 E-mail : sasabayashi-opir@jpma.or.jp URL : http://www.jpma.or.jp/opir/ 3 4 5 6 1 2 3 4 1 2 3 4 5 6 7 8 9 10 11 2013 2014
medical product information 74
73 medical product information medical product information 74 75 medical product information 76 medical product information 77 medical product information 78 medical product information 79 medical product
FX ) 2
(FX) 1 1 2009 12 12 13 2009 1 FX ) 2 1 (FX) 2 1 2 1 2 3 2010 8 FX 1998 1 FX FX 4 1 1 (FX) () () 1998 4 1 100 120 1 100 120 120 100 20 FX 100 100 100 1 100 100 100 1 100 1 100 100 1 100 101 101 100 100
1 93 1. 2. 3.
16 1 93 1. 2. 3. 2 93 4. 5. 17 6. 7. 3 93 4 93 5 93 6 93 ( ) 7 93 8 93 9 93 10 93 11 93 12 93 16 12 24 13 93 1 1 1 14 93 15 93 5 16 93 17 93 50% 50% 18 93 2.5% 0.25% 1/2(= 2 1 1 25 19 93 20 93 21 93 22
13 5 1 217.49 19.5 19.3 1 (10) (11) (4) 2 () 1 2 3 1 () 32 1 46 6 () 4 () (17) (74) 5 6 61 ー 7 () ( ) 8 9 10 11 12 27 31 5 13 829-1844 620-2654 669-6054 646-3054 681-6054 840-6054 856-6164 829-6124 844-7164
Microsoft Word - 表紙資料２－４
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
EPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
ありがとうございました
- 1 - - 2 - - 3 - - 4 - - 5 - 1 2 AB C A B C - 6 - - 7 - - 8 - 10 1 3 1 10 400 8 9-9 - 2600 1 119 26.44 63 50 15 325.37 131.99 457.36-10 - 5 977 1688 1805 200 7 80-11 - - 12 - - 13 - - 14 - 2-1 - 15 -
EPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
公務員人件費のシミュレーション分析
47 50 (a) (b) (c) (7) 11 10 2018 20 2028 16 17 18 19 20 21 22 20 90.1 9.9 20 87.2 12.8 2018 10 17 6.916.0 7.87.4 40.511.6 23 0.0% 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2.0% 4.0% 6.0% 8.0%
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 A B (A/B) 1 1,185 17,801 6.66% 2 943 26,598 3.55% 3 3,779 112,231 3.37% 4 8,174 246,350 3.32% 5 671 22,775 2.95% 6 2,606 89,705 2.91% 7 738 25,700 2.87% 8 1,134
橡hashik-f.PDF
1 1 1 11 12 13 2 2 21 22 3 3 3 4 4 8 22 10 23 10 11 11 24 12 12 13 25 14 15 16 18 19 20 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 144 142 140 140 29.7 70.0 0.7 22.1 16.4 13.6 9.3 5.0 2.9 0.0
198
197 198 199 200 201 202 A B C D E F G H I J K L 203 204 205 A B 206 A B C D E F 207 208 209 210 211 212 213 214 215 A B 216 217 218 219 220 221 222 223 224 225 226 227 228 229 A B C D 230 231 232 233 A
ネットショップ・オーナー２ ユーザーマニュアル
1 1-1 1-2 1-3 1-4 1 1-5 2 2-1 A C 2-2 A 2 C D E F G H I 2-3 2-4 2 C D E E A 3 3-1 A 3 A A 3 3 3 3-2 3-3 3-4 3 C 4 4-1 A A 4 B B C D C D E F G 4 H I J K L 4-2 4 C D E B D C A C B D 4 E F B E C 4-3 4
1
1 2 3 4 5 (2,433 ) 4,026 2710 243.3 2728 402.6 6 402.6 402.6 243.3 7 8 20.5 11.5 1.51 0.50.5 1.5 9 10 11 12 13 100 99 4 97 14 A AB A 12 14.615/100 1.096/1000 B B 1.096/1000 300 A1.5 B1.25 24 4,182,500
05[ ]戸田(責)村.indd
![05[ ]戸田(責)村.indd](/thumbs/91/106164845.jpg "05[ ]戸田(責)村.indd")
147 2 62 4 3.2.1.16 3.2.1.17 148 63 1 3.2.1.F 3.2.1.H 3.1.1.77 1.5.13 1 3.1.1.05 2 3 4 3.2.1.20 3.2.1.22 3.2.1.24 3.2.1.D 3.2.1.E 3.2.1.18 3.2.1.19 2 149 3.2.1.23 3.2.1.G 3.1.1.77 3.2.1.16 570 565 1 2
/9/ ) 1) 1 2 2) 4) ) ) 2x + y 42x + y + 1) 4) : 6 = x 5) : x 2) x ) x 2 8x + 10 = 0
1. 2018/9/ ) 1) 8 9) 2) 6 14) + 14 ) 1 4 8a 8b) 2 a + b) 4) 2 : 7 = x 8) : x ) x ) + 1 2 ) + 2 6) x + 1)x + ) 15 2. 2018/9/ ) 1) 1 2 2) 4) 2 + 6 5) ) 2x + y 42x + y + 1) 4) : 6 = x 5) : x 2) x 2 15 12
NEDO
10 MRI 1 1 595% 5 IOR 100% MRI MRI MRI MRI MRI MRI 11 MRI 3 2 1 MRI 1 1.5 0.000005 100 5 MRI MRI MRI MRI MRI MRI MRI MRI MRI (1) MRI MRI 0.3 3 MRI 1 / (2) MRI MRI (3)MRI MRI 3 (4)MRI MRI MRI (5)MRI 2006
2007.3„”76“ƒ
76 19 27 19 27 76 76 19 27 19 27 76 76 19 27 19 27 76 76 19 27 19 27 76 1,27, 2, 88, 8,658 27, 2,5 11,271,158 1,712,876 21,984,34 1,, 6, 7, 2, 1,78, 1,712,876 21,492,876 27, 4, 18, 11,342 27, 2,5 491,158
1631 70
70 1631 1631 70 70 1631 1631 70 70 1631 1631 70 70 1631 1631 70 70 1631 1631 70 70 1631 9,873,500 9,200,000 673,500 2,099,640 2,116,000 16,360 45,370 200,000 154,630 1,000,000 1,000,000 0 648,851 730,000
72 1731 1731 72 72 1731 1731 72 72 1731 1731 72 72 1731 1731 72 72 1731 1731 72 12,47,395 4, 735,5 1,744 4,5 97, 12,962,139 6,591,987 19,554,126 9,2, 4, 7, 2, 9,96, 6,591,987 16,551,987 2,847,395 35,5
肝臓病教室201207v2配布用.pptx
24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0
,
23 3 23 3 15 3.7 21 44,612 22 46,28 3.4 21 1,185 22 1,53 9,283 2 4,435 6 8.1 21 35,956 22 38,864 67.1 21 379 22 633 12,745 2.6 1.1 No.84 15 6 24 1 11 1 21 22 3.2 1.4 2291 22 4 2 5 15 1 6 5 1998 1999 11
n=360 28.6% 34.4% 36.9% n=360 2.5% 17.8% 19.2% n=64 0.8% 0.3% n=69 1.7% 3.6% 0.6% 1.4% 1.9% < > n=218 1.4% 5.6% 3.1% 60.6% 0.6% 6.9% 10.8% 6.4% 10.3% 33.1% 1.4% 3.6% 1.1% 0.0% 3.1% n=360 0% 50%
104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26
25 25 3 5 MMR 1 104 100 60 9,195,336 409 0.004 24 8 31 9,025,983 568 0.006 2012 8 31 6,634,686 956 ( 0.014 ) 2 2011 8 26 2012 8 31 1,032,660 132 ( 0.013 ) 3 2010 6 11 3 11 15.4 1 1 ( ) 12 2 2 3 ER ) (
http://banso.cocolog-nifty.com/ 100 100 250 5 1 1 http://www.banso.com/ 2009 5 2 10 http://www.banso.com/ 2009 5 2 http://www.banso.com/ 2009 5 2 http://www.banso.com/ < /> < /> / http://www.banso.com/
(1)...3 (2)...5 (3)...6 (4) (1)...9 (2)...10 (3)...13 (4) 14 (5) (1)...16 (2) (1)...21 (2)...22 (3)
...1...3...3 (1)...3 (2)...5 (3)...6 (4)...7...9 (1)...9 (2)...10 (3)...13 (4) 14 (5)...15...16 (1)...16 (2)...19...21 (1)...21 (2)...22 (3)...24...26...26 (1)...26 (2)...28 (3)...30 (4)...31 (5)...35
, 1. x 2 1 = (x 1)(x + 1) x 3 1 = (x 1)(x 2 + x + 1). a 2 b 2 = (a b)(a + b) a 3 b 3 = (a b)(a 2 + ab + b 2 ) 2 2, 2.. x a b b 2. b {( 2 a } b )2 1 =
x n 1 1.,,.,. 2..... 4 = 2 2 12 = 2 2 3 6 = 2 3 14 = 2 7 8 = 2 2 2 15 = 3 5 9 = 3 3 16 = 2 2 2 2 10 = 2 5 18 = 2 3 3 2, 3, 5, 7, 11, 13, 17, 19.,, 2,.,.,.,?.,,. 1 , 1. x 2 1 = (x 1)(x + 1) x 3 1 = (x 1)(x
活用ガイド（ハードウェア編）
4 5 6 1 2 3 7 8 MITSUBISHI ELECTRIC INFORMATION TECHNOLOGY CORPORATION 2010 9 PART 1 10 11 PART 2 PART 3 12 PART 4 PART 5 13 P A R T 1 16 1 17 18 1 19 20 1 21 22 1 1 2 23 1 2 3 4 24 1 25 26 1 27 1 2 3
- 16 M7.3 14 M6.5 - - - - - A-4 A-5 A-3 F-3 F-1 C-3 G-1,E-6 C-2 D-1 F-2 E-7 J-1 J-3 B-3 K-1 B-3 I-4 I-3 I-2 I-6 C-1 I-5 B-5 B-2 J-2 A-1 A-2 E-1 B-4 I-1 E-2 E-5 B-1,E-4 E-3 A-1 A-2 A-2 A-3 A-4 A-5 A-2
政策研ニュースNo27
Views and Actions Points of View IMS World Review IMS Health Pfizer Johnson & Johnson Merck & Co Abbott Eli Lilly Amgen Wyeth Bristol Myers Squibb Schering Plough ForestBaxterMylanGlaxoSmithKline Novartis
橡アロマセラピー症状別処方例.PDF
1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20
がん診療におけるFDG FDG-PET/CTの役割
PET/CT PET/CT MRI PET PET/CT Kurashiki Central Hospital FDG-PET CT PET/CT (stage1) FDG-PET (stage1) PET/CT FDG-PET PET/CT (stage4) FDG-PET (stage4) PET/CT FDG-PET PET/CT PET/CT
バイオ医薬品における特許の現状
18 1 1 2 2 7 1970 3 DNA 4 5 A REMICADE TM 6 6-506120 New York University, Centocor, Inc. 1 1 TNF a A2 TNF b TNF HERCEPTIN TM HUMIRA TM Genentech G HERCEPTIN trastuzumab 1998 FDA HER2 HER2 7 HERCEPTIN HERCEPTIN
untitled
280 200 5 7,800 6 8,600 28 1 1 18 7 8 2 ( 31 ) 7 42 2 / / / / / / / / / / 1 3 (1) 4 5 3 1 1 1 A B C D 6 (1) -----) (2) -- ()) (3) ----(). ()() () ( )( )( )( ) ( ) ( )( )( )( ) () (). () ()() 7 () ( ) 1
障害者職域拡大カリキュラム研究会中間報告書構成案
3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16
合併後の交付税について
(1) (2) 1 0.9 0.7 0.5 0.3 0.1 2 3 (1) (a), 4 (b) (a), (c) (a) 0.9 0.7 0.5 0.3 0.1 (b) (d),(e) (f) (g) (h) (a) (i) (g) (h) (j) (i) 5 (2) 6 (3) (A) (B) (A)+(B) n 1,000 1,000 2,000 n+1 970 970 1,940 3.0%
JAPIC Pharma Report 海外医薬情報 ( 承認情報 ) JAPIC Pharma Report 海外医薬情報 2017 年 10 月号 ( 承認情報 ) 海外における医薬品の承認関連情報 承認, 承認勧告, 承認申請, 発売等に分類して掲載 承認 有効成分 ( 商品名 ) 会社名 薬
JAPIC Pharma Report 海外医薬情報 2017 年 10 月号 ( 承認情報 ) 海外における医薬品の承認関連情報 承認, 承認勧告, 承認申請, 発売等に分類して掲載 承認 有効成分 ( 商品名 ) 会社名 薬効または適応 国名 情報源 belimumab(benlysta) GlaxoSmithKline PLC 全身性エリテマトーデス ( 自己 注射用皮下投与製剤 )( 新剤
54 144 144 144 144 144 80 152 84 122 HTML
54 144 144 144 144 144 80 152 84 122 HTML P20 P24 P28 P40 P54 P84 P122 P138 P144 P152 P220 P234 P240 P242 1 1-1 1-2 1-3 1-4 1-5 1 1-6 1 2 2-1 2-2 A C D E F 2 G H I 2-3 2-4 C D E E A 2
2
1 2 3 1) 2) 3) 2 3 1 2 3 4 5 6 7 8 9 10 11 4 12 13 14 15 X 16 X 17 X CT 18 MRI 19 20 4 A. ENG T&T B. ABLB SISI ABR ASSRMLRSRL 5 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 6 1 2 3 4 7 1 POS( Problem
2012カーエレクトロニクスカタログ
Car electronics 01 Car electronics Car electronics 02 03 Car electronics Car electronics 04 05 Car electronics Car electronics 06 07 Car electronics Car electronics 08 09 Car electronics Car electronics
１ 発病のとき
1 3 2002 11 26 27 5 2003 1 15 16 9 2003 4 16 17 10 2003 6 25 26 12 2003 9 17 13 2003 11 12 13 16 2004 4 21 22 17 2004 5 19 20 18 2004 6 15 17 2004 6 17 20 2004 7 14 15 21 2004 8 18 19 2004 8 19 22 2004
１
Jetro technology bulletin-2005/12 477 2005/12, No.477...1...2 1....2 1-1....2 1-2...3 1-3...5 2....6 3....7 3-1...7 3-2...8 3-3...8 4....8 4-1...8 4-2...9 4-3...9 5....11...12 1....12 2....15 2-1...15
- 1 -
- 1 - HIV cmc cmc - 2 - cmc() ( ) 5-3 - - 4 - (1) (2) (3) ( ) - 5 - 0537-73-2662 0537-35-2971 0548-63-1251 9 00 16 00-6 - - 7 - 2 3 4 5 6 1,328 1,848 2,368 2,888 3,408-8 - - 9 - - 10 - - 11 - 3-12 - (
2012 10 7,150 8 22 3,159 2,457 78656 21 30 87 330 289 940 456 1450 681 22 60 803 2570 536 1780 251 8 1 2,475 78%2 374 12% 1 342 2 312 3 215 1 1,025 2 753 3 90 1 1,937 612 612 203 136 4 1 2 1,085
00 0 0 0 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.... 0........ 0 0 0 0 0 0 0 0 0 0..0..........0 0 0 0 0 0 0 0 0 0 0.... 0........ 0 0 0 0 0 0 0 0 0 0... 0...... 0... 0 0 0 0 0 0..0 0... 0 0 0 0 0.0.....0.
